WallStSmart
ACXP

Acurx Pharmaceuticals LLC

NASDAQ: ACXP · HEALTHCARE · BIOTECHNOLOGY

$2.18
-5.08% today

Updated 2026-06-05

Market cap
$6.75M
P/E ratio
P/S ratio
EPS (TTM)
$-3.79
Dividend yield
52W range
$1 – $15
Volume
0.1M

Acurx Pharmaceuticals LLC (ACXP) Financial statements

SEC filings — annual and quarterly data.

Cash flow — annual

Item2019202020212022202320242025
Operating cash flow$-3.99M$-3.35M$-5.01M$-7.54M$-9.80M$-10.38M$-6.79B
Capital expenditures$0.00$0.00$3.00$0.00$5.00$0.00$0.00
Depreciation
Stock-based comp$900431.00$1.27M$6.74M$3.30M$3.77M$3.44M$1.25B
Free cash flow$-3.99M$-3.35M$-5.01M$-7.54M$-9.80M$-10.38M$-6.79B
Investing cash flow
Financing cash flow
Dividends paid
Share repurchases
Debt repayment
Net change in cash

Frequently asked questions

How much free cash flow does ACXP generate?

ACXP produced $-6.79B in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is ACXP's balance sheet healthy?

ACXP holds $7.56B in cash and equivalents against — in long-term debt, on $5.27M of shareholder equity. That debt is best read against the cash flow the business throws off each year.